Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Chatta · SciRah

Researcher profile · Semantic Scholar

G. Chatta

Share profile

G. Chatta — researcher profile on SciRah

h-index: 43
Works: 188
Citations: 6,013

Most-cited papers

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
M. S. van der Heijden, G. Sonpavde, T. Powles, A. Necchi +20 more
2023New England Journal of Medicine391 citations Open access
Semantic Scholar
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain +12 more
2021Nature Communications159 citations Open access
Semantic Scholar
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Qiuhui Li, Qu Deng, Hsueh-Ping Chao, Xin Liu +21 more
2018Nature Communications127 citations Open access
Semantic Scholar
Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance
Anmbreen Jamroze, G. Chatta, Dean G. Tang
2021Cancer Letters124 citations Open access
Semantic Scholar
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma
D. Reece, D. Sullivan, S. Lonial, A. Mohrbacher +11 more
2010Cancer Chemotherapy and Pharmacology111 citations Open access
Semantic Scholar
Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
Sherrie L. Aspinall, C. B. Good, Xinhua Zhao, F. Cunningham +36 more
2015BMC Cancer99 citations Open access
Semantic Scholar
Phase II Study of Aflibercept (VEGF-Trap) in Patients with Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial
P. Twardowski, W. Stadler, P. Frankel, P. Lara +5 more
2010Urology92 citations Open access
Semantic Scholar
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
N. Berinstein, Mohan Karkada, M. Morse, J. Nemunaitis +9 more
2012Journal of Translational Medicine86 citations Open access
Semantic Scholar
Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer
Swathi Ramakrishnan, V. Granger, Monika Rak, Qiang Hu +12 more
2019Cell Death and Differentiation85 citations Open access
Semantic Scholar
High intratumoral CD8+ T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy
Yuan-Quan Yang, K. Attwood, W. Bshara, J. Mohler +4 more
2020The Prostate82 citations Open access
Semantic Scholar
Functional reprogramming of human prostate cancer to promote local attraction of effector CD8+ T cells
Ravikumar Muthuswamy, J. Corman, Kathryn Dahl, G. Chatta +1 more
2016The Prostate66 citations
Semantic Scholar
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib
A. Loehr, A. Hussain, A. Patnaik, A. Bryce +17 more
2022European Urology61 citations Open access
Semantic Scholar
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
P. Twardowski, J. Beumer, Chien S. Chen, A. Kraft +5 more
2013Anti-Cancer Drugs56 citations Open access
Semantic Scholar
Serum metabolic profiling identified a distinct metabolic signature in Bladder Cancer Smokers: A key metabolic enzymes associated with patient survival
C. Amara, Chandrashekar R. Ambati, Venkatrao Vantaku, D. Piyarathna +12 more
2019Cancer Epidemiology, Biomarkers and Prevention43 citations Open access
Semantic Scholar
A Double Blind Randomized Crossover Study of Oral Thalidomide versus Placebo in Patients with Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation
W. Figg, M. Hussain, J. Gulley, P. Arlen +9 more
2009Journal of Urology41 citations Open access
Semantic Scholar
Type-1 Polarized Dendritic Cells Loaded with Apoptotic Prostate Cancer Cells Are Potent Inducers of CD8+ T cells against Prostate Cancer Cells and Defined Prostate Cancer-Specific Epitopes
E. Wieckowski, G. Chatta, R. Mailliard, W. Gooding +3 more
2010The Prostate36 citations Open access
Semantic Scholar
Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer
Swathi Ramakrishnan, Qiang Hu, N. Krishnan, Dan Wang +13 more
2017Cell Death and Disease30 citations Open access
Semantic Scholar
Identification of targets for prostate cancer immunotherapy
A. Papanicolau-Sengos, Yuan-Quan Yang, S. Pabla, Felicia L. Lenzo +8 more
2019The Prostate27 citations
Semantic Scholar
NFκB-Activated COX2/PGE2/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues
O. M. Ibrahim, P. Basse, Weijian Jiang, K. Guru +2 more
2021Cancers26 citations Open access
Semantic Scholar
A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).
D. Petrylak, N. Vogelzang, G. Chatta, M. Fleming +16 more
201525 citations
Semantic Scholar
Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
M. Dolan, M. Mastri, A. Tracz, J. Christensen +2 more
2019PLoS ONE23 citations Open access
Semantic Scholar
A randomized phase II study of pazopanib in hormone sensitive prostate cancer: a University of Chicago Phase II Consortium/ Department of Defense Prostate Cancer Clinical Trials Consortium study
J. E. Ward, T. Karrison, G. Chatta, M. Hussain +5 more
2011Prostate Cancer and Prostatic Diseases23 citations Open access
Semantic Scholar
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879
D. Quinn, D. Tsao-Wei, P. Twardowski, A. Aparicio +9 more
2021Investigational new drugs22 citations
Semantic Scholar
Cancer chemotherapy in the elderly patient.
T. L. Gillison, G. Chatta
2010Oncology20 citations
Semantic Scholar
Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells
J. Kirk, Jie Wang, M. Long, S. Rosario +17 more
2024Cell Stem Cell19 citations Open access
Semantic Scholar
Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemness
Xiaozhuo Liu, Wen Li, I. Puzanov, D. Goodrich +2 more
2022Essays in Biochemistry19 citations Open access
Semantic Scholar
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing
G. Dy, M. Nesline, A. Papanicolau-Sengos, P. DePietro +27 more
2019BMC Medical Informatics and Decision Making18 citations Open access
Semantic Scholar
Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC).
A. Laccetti, G. Chatta, N. Iannotti, C. Kyriakopoulos +3 more
2023Journal of Clinical Oncology16 citations
Semantic Scholar
ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).
M. Taplin, A. Hussain, Satish Shah, N. Shore +16 more
2019Journal of Clinical Oncology16 citations
Semantic Scholar
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice
Richard W. Joseph, G. Chatta, U. Vaishampayan
2017Urologic oncology15 citations Open access
Semantic Scholar
Oncologist uptake of comprehensive genomic profile guided targeted therapy
M. Nesline, P. DePietro, G. Dy, A. Early +18 more
2019OncoTarget14 citations Open access
Semantic Scholar
TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
W. Abida, A. Bryce, A. Balar, G. Chatta +16 more
201814 citations
Semantic Scholar
776P Phase II trial of concurrent nivolumab in urothelial bladder cancer with radiation therapy in localized/locally advanced disease for chemotherapy ineligible patients [NUTRA trial]
U. Vaishampayan, L. Heilbrun, N. Vaishampayan, C. Li +7 more
202013 citations Open access
Semantic Scholar
Role of tumor microenvironment in the efficacy of BCG therapy
O. M. Ibrahim, R. Pandey, G. Chatta, P. Kalinski
2020Trends in Research13 citations Open access
Semantic Scholar
Phase 1b Trial of Proteasome Inhibitor Carfilzomib with Irinotecan in Lung Cancer and Other Irinotecan-Sensitive Malignancies that have Progressed on Prior Therapy (Onyx IST Reference Number: CAR-IST-553)
S. Arnold, K. Chansky, M. Leggas, M. Thompson +6 more
2017Investigational new drugs11 citations Open access
Semantic Scholar
Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot‐assisted radical cystectomy for muscle‐invasive bladder cancer: Results from the International Robotic Cystectomy Consortium
D. Gopalakrishnan, A. Elsayed, A. Hussein, Z. Jing +16 more
2021International journal of urology10 citations Open access
Semantic Scholar
A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer
Dongbo Xu, Q. Cao, Li Wang, Jianmin Wang +11 more
2022Molecular Cancer Therapeutics9 citations Open access
Semantic Scholar
Abstract CT094: Phase Ib results of ProSTAR: CPI-1205, EZH2 inhibitor, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC)
M. Taplin, A. Hussain, Satish Shah, N. Shore +20 more
2019Clinical Trials9 citations
Semantic Scholar
Phase Ib trial of enzalutamide (Enza) with venetoclax (Ven) in metastatic castration-resistant prostate cancer (mCRPC).
S. Perimbeti, Anmbreen Jamroze, K. Attwood, Bailey K. Farmer +7 more
2023Journal of Clinical Oncology8 citations
Semantic Scholar
Medicaid Expansion and Racial Disparity in Timely Multidisciplinary Treatment in Muscle Invasive Bladder Cancer.
Changchuan Jiang, S. Perimbeti, L. Deng, Jiazhang Xing +3 more
2023Journal of the National Cancer Institute8 citations
Semantic Scholar
Patient derived models of bladder cancer enrich the signal of the tumor cell transcriptome facilitating the analysis of the tumor cell compartment.
M. Mastri, Swathi Ramakrishnan, Shruti Shah, E. Karasik +9 more
2021American journal of clinical and experimental urology8 citations
Semantic Scholar
Immunobiology of Dendritic Cells in Cancer
M. Shurin, A. Keskinov, G. Chatta
20147 citations
Semantic Scholar
A phase I study of the safety and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with advanced-stage ovarian, breast, or prostate cancer.
N. Berinstein, Michael A. Morse, Howard L. Kaufman, J. Nemunaitis +8 more
2011Journal of Clinical Oncology7 citations
Semantic Scholar
Association of high CD8+ tumor infiltrating lymphocytes at prostatectomy with improved survival of prostate cancer patients.
Yuan-Quan Yang, K. Attwood, Cassandra L. Versaggi, A. Omilian +12 more
20185 citations
Semantic Scholar
Archexin, a novel AKT-1–specific inhibitor for the treatment of metastatic renal cancer: Preliminary phase I data.
S. Tagawa, G. Chatta, R. Mazhari, E. Benaim
20165 citations
Semantic Scholar
Spur cell hemolytic anemia in liver failure
Colin Murphy, Shweta Jain, Daniel E. Sabath, G. Chatta +1 more
2016Transfusion5 citations
Semantic Scholar
Abstract CT329: Phase I study of the PI3Kβ/δ inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding
L. Siu, J. de Bono, Kari B. Wisinski, C. Higano +11 more
20155 citations
Semantic Scholar
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
N. Berinstein, Mohan Karkada, M. Morse, J. Nemunaitis +9 more
2012Journal of Translational Medicine5 citations Open access
Semantic Scholar
First-inman application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian , breast and prostate cancer patients
N. Berinstein, Mohan Karkada, M. Morse, J. Nemunaitis +9 more
20125 citations
Semantic Scholar
c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naïve prostate cancer that retains RB expression.
W. Kelly, J. L. Godwin, J. Hoffman-Censits, K. Knudsen +12 more
20184 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Guru×8
Invite
K. Guru — researcher profile on SciRah
K. Attwood×7
Invite
K. Attwood — researcher profile on SciRah
K. Odunsi×7
Invite
K. Odunsi — researcher profile on SciRah
C. Morrison×6
Invite
C. Morrison — researcher profile on SciRah

×6

Invite

P. Kalinski — researcher profile on SciRah

Dean G. Tang×5

Invite

Dean G. Tang — researcher profile on SciRah

Invite

A. Hussain — researcher profile on SciRah

Invite

I. Puzanov — researcher profile on SciRah

N. Berinstein×4

Invite

N. Berinstein — researcher profile on SciRah

Mohan Karkada×4

Invite

Mohan Karkada — researcher profile on SciRah

Invite

R. Nigam — researcher profile on SciRah

Lisa D. MacDonald×4

Invite

Lisa D. MacDonald — researcher profile on SciRah